Top

Published in:

01-10-2009 | Preclinical Study

Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model

Authors: Rachel L. Ruhlen, Dana M. Willbrand, Cynthia L. Besch-Williford, Lixin Ma, James D. Shull, Edward R. Sauter

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Abstract

The ACI rat is a unique model of human breast cancer in that mammary cancers are induced by estrogen without carcinogens, irradiation, xenografts or transgenic manipulations. We sought to characterize mammary cancers in a congenic variant of the ACI rat, the ACI.COP-Ept2. All rats with estradiol implants developed mammary cancers in 5–7 months. Rats bearing estradiol-induced mammary cancers were treated with tamoxifen for three weeks. Tamoxifen reduced tumor mass, measured by magnetic resonance imaging, by 89%. Tumors expressed estrogen receptors (ER), progesterone receptor (PR), and Erbb2. ERα and PR were overexpressed in tumor compared to adjacent non-tumor mammary gland. Thus, this model is highly relevant to hormone responsive human breast cancers.

Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270–282PubMedCrossRef

Anonymous: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on hormonal factors in breast cancer.[see comment][erratum appears in Lancet 1997 Nov 15;350(9089):1484]. Lancet 1997, 350(9084):1047–1059

Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288(3):321–333PubMedCrossRef

Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project p-1 study. [see comment]. J Natl Cancer Inst 90(18):1371–1388PubMedCrossRef

Shull JD, Spady TJ, Snyder MC et al (1997) Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis 18(8):1595–1601PubMedCrossRef

Spady TJ, Harvell DM, Snyder MC et al (1998) Estrogen-induced tumorigenesis in the Copenhagen rat disparate susceptibilities to development of prolactin-producing pituitary tumors and mammary carcinomas. Cancer Lett 124(1):95–103PubMedCrossRef

Shull JD, Pennington KL, Reindl TM et al (2001) Susceptibility to estrogen-induced mammary cancer segregates as an incompletely dominant phenotype in reciprocal crosses between the ACI and Copenhagen rat strains. Endocrinology 142(12):5124–5130PubMedCrossRef

Gould KA, Tochacek M, Schaffer BS et al (2004) Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics 168(4):2113–2125PubMedCrossRef

Schaffer BS, Lachel CM, Pennington KL et al (2006) Genetic bases of estrogen-induced tumorigenesis in the rat: mapping of loci controlling susceptibility to mammary cancer in a Brown Norway × ACI intercross. Cancer Res 66(15):7793–7800PubMedCrossRef

10.

Shull JD (2007) The rat oncogenome: comparative genetics and genomics of rat models of mammary carcinogenesis. Breast Dis 28:69–86PubMed

11.

Li JJ, Papa D, Davis MF et al (2002) Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. Mol Carcinog 33(1):56–65PubMedCrossRef

12.

Blank EW, Wong P-Y, Lakshamanaswamy R et al (2008) Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. Proc Natl Acad Sci USA 105(9):3527–3532PubMedCrossRef

13.

Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148):1087–1093PubMedCrossRef

14.

Harvell DM, Strecker TE, Tochacek M et al (2000) Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proceedings of the National Academy of Sciences of the United States of America 97(6):2779–2784PubMedCrossRef

15.

Li JJ, Weroha SJ, Lingle WL et al (2004) Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci USA 101(52):18123–18128PubMedCrossRef

16.

Adamovic T, Roshani L, Chen L et al (2007) Nonrandom pattern of chromosome aberrations in 17beta-estradiol-induced rat mammary tumors: indications of distinct pathways for tumor development. Genes Chromosomes Cancer 46(5):459–469PubMedCrossRef

17.

Harvell DM, Strecker TE, Xie B et al (2002) Dietary energy restriction inhibits estrogen-induced mammary, but not pituitary, tumorigenesis in the ACI rat. Carcinogenesis 23(1):161–169PubMedCrossRef

18.

Aiyer HS, Srinivasan C, Gupta RC (2008) Dietary berries and ellagic acid diminish estrogen-mediated mammary tumorigenesis in ACI rats. Nutr Cancer 60(2):227PubMedCrossRef

19.

Spady TJ, Harvell DM, Lemus-Wilson A et al (1999) Modulation of estrogen action in the rat pituitary and mammary glands by dietary energy consumption. J Nutr 129(2S Suppl):587S–590SPubMed

20.

Strecker TE, Spady TJ, Schaffer BS et al (2005) Genetic bases of estrogen-induced pituitary tumorigenesis: identification of genetic loci determining estrogen-induced pituitary growth in reciprocal crosses between the ACI and Copenhagen rat strains. Genetics 169(4):2189–2197PubMedCrossRef

21.

Kurz SG, Hansen KK, McLaughlin MT et al (2008) Tissue Specific Actions of the Ept1, Ept2, Ept6 and Ept9 genetic determinants of responsiveness to estrogens in the female rat. Endocrinology 149(8):3850–3859PubMedCrossRef

22.

Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60(5):1306–1311PubMed

23.

Fulton AM, Gimotty P, Alonsozana E et al (2000) Elevated prostaglandin E2 (PGE2) levels in human breast cancer are associated with poor long-term survival. Proc Am Assn Cancer Res 41:3660A

24.

Ristimaki A, Sivula A, Lundin J et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632–635PubMed

25.

Norman A, Litwack G (1997) Hormones, 2nd edn. Academic Press, San Diego

26.

Spady TJ, Pennington KL, McComb RD et al (1999) Estrogen-induced pituitary tumor development in the ACI rat not inhibited by dietary energy restriction. Mol Carcinog 26(4):239–253PubMedCrossRef

27.

Ravoori S, Vadhanam MV, Sahoo S et al (2007) Mammary tumor induction in ACI rats exposed to low levels of 17beta-estradiol. Int J Oncol 31(1):113–120PubMed

28.

Li SA, Weroha SJ, Tawfik O et al (2002) Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: evidence for estrogen receptor mediation. J Endocrinol 175(2):297–305PubMedCrossRef

29.

Yankeelov TE, DeBusk LM, Billheimer DD et al (2006) Repeatability of a reference region model for analysis of murine DCE-MRI data at 7T. J Magn Reson Imaging 24(5):1140–1147PubMedCrossRef

30.

Rowland DJ, Garbow JR, Laforest R et al (2005) Registration of [18F]FDG microPET and small-animal MRI. Nucl Med Biol 32(6):567–572PubMedCrossRef

31.

Turetschek K, Preda A, Floyd E et al (2003) MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. Eur J Nucl Med Mol Imaging 30(3):448–455PubMed

32.

Marzola P, Ramponi S, Nicolato E et al (2005) Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents. Invest Radiol 40(7):421–429PubMedCrossRef

33.

Dunn BK, Wickerham DL, Ford LG (2005) Prevention of hormone-related cancers: breast cancer. J Clin Oncol 23(2):357–367PubMedCrossRef

34.

Banks E, Beral V, Bull D et al (2003) Breast cancer and hormone-replacement therapy in the million women study. Lancet 362:419–427CrossRef

35.

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER–2/neu oncogene. Science 235(4785):177–182PubMedCrossRef

36.

Harris RE, Beebe-Donk J, Alshafie GA (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27PubMedCrossRef

Title: Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model
Authors: Rachel L. Ruhlen
Dana M. Willbrand
Cynthia L. Besch-Williford
Lixin Ma
James D. Shull
Edward R. Sauter
Publication date: 01-10-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0169-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Never use anthracyclines with trastuzumab: it is time to reconsider the taboo

Lymphatic drainage in the muscle and subcutis of the arm after breast cancer treatment

Measuring lymphedema in patients with breast cancer: go with the flow?

Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance

Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer

Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer